The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
This is not new news, the issue seems to be no warming message on the label , the science is clear
Recent scientific research and clinical studies have shown that infant formulas made from cow’s milk (e.g., Similac and Enfamil) significantly increase the risk of NEC occurring in premature infants.
A study published in 2009 evaluated the health benefits of an exclusively human milk-based diet as compared to a diet with both human milk and cow’s milk-based products in extremely premature infants. The results show that preterm babies fed an exclusively human milk-based diet were 90% less likely to develop surgical NEC as compared to a diet that included some cow’s milk-based products. S. Sullivan, et al, An Exclusively Human Milk-Based Diet Is Associated with a Lower Rate of Necrotizing Enterocolitis than a Diet of Human Milk and Bovine Milk-Based Products, JOURNAL OF PEDIATRICS, 156: 562-7 (2010) (emphasis added). In 2011, the U.S. Surgeon General published a report stating that premature infants who are not breastfed are 138% more likely to develop NEC.
Doing business in the US as a UK company is full of risk , look at BP and the 50bn hit they took over the years , it’s not a level playing field in the courts out there , take a look at Boeing , do not see them in court and there is a lot they have got wrong, very worrying for Reckitts
This company has the potential to grow dramatically, it has pivoted from the old days of brain juicer doing clever learning based surveys to being a market leading agency for testing advertising, 29m revenue, strong margins and valued at only 43m, very strong buy
Remember the multinationals and brand owners pay for the advertising and they decide where they want their brands to be seen not TRMR so it’s a balance otherwise they walk away from TRMR as it damages the brands